Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Nebulized Revefenacin Inhalation Solution in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).

NCT05046795 is registered in ClinicalTrials.gov with Mylan Pharma UK Ltd. as lead sponsor.

NCT NCT05046795
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05046795 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double Blind, Placebo-Controlled, Parallel Group Study of Nebulized Revefenacin Inhalation Solution in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD).
Lead sponsor
Mylan Pharma UK Ltd.
Phase
Phase 3
Overall status
Completed
Start date
November 10, 2021
Completion date
July 26, 2023
Enrollment
258 (actual)
Sites
35

Conditions

As the registry lists them; a condition with its own page is linked.

copd